Method for enhancing outflow of aqueous humor in treatment of glaucoma

• US 6,228,873 B1
• Filed: 06/08/1998
• Issued: 05/08/2001
• Est. Priority Date: 12/09/1994
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: O'Donnell, Martha E., Brandt, James D., Curry, Fitz-Roy E.
• Primary Examiner(s): Spivack, Phyllis G.
• Application Number:
  US09/093,961
• Time in Patent Office: 1,065 Days
• Field of Search: 514/347, 514/428, 514/471, 514/562
• US Class Current: 514/347
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 31/402 1-aryl substituted, e.g. piretanide
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof

Abstract

Elevated intra-ocular pressure is reduced by administration directly to the eye of compounds that inhibit function of a Na⁺—K⁺—2Cl⁻² cotransporter mechanism discovered in trabecular meshwork cells of mammalian eyes. These compounds are useful in treatment of diseases of the eye associated with elevated intra-ocular pressure, such as ocular hypertension and glaucoma. A screening method is provided to discover additional compounds with utility for lowering intra-ocular pressure by substantially inhibiting the Na⁺—K^+—Cl−2 cotransporter mechanism in trabecular meshwork cells.

Claims

1. A method for increasing aqueous humor outflow in the eye of a mammalian patient to reduce the intra-ocular pressure therein, said method comprising administering to said eye a composition comprising an effective amount of a compound that inhibits the Na⁺—

K⁺—

2Cl⁻

co-transporter in the trabecular meshwork of the eye, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the patient is human and administration is in treatment of glaucoma.

3. The method of claim 2 wherein dosage of the compound is 50-100 microliters of a 5-10 mM solution of the compound per day.

22. The method of claim 2 wherein the compound is piretanide, or a pharmaceutically acceptable salt thereof.

4. A method for increasing aqueous humor outflow in the eye of a mammalian patient to reduce the intra-ocular pressure therein, said method comprising administering to said eye a composition comprising an effective amount of a compound that inhibits the Na⁺—

K⁺—

2Cl⁻

co-transporter in the trabecular meshwork of the eye, said compound selected from the group consisting of high ceiling diuretics.

5. The method of claim 4 wherein the compound is selected from the group consisting of furosemide, torasemide, piretanide and pharmaceutically acceptable salts thereof.

6. The method of claim 4 wherein the compound is furosemide, or a pharmaceutically acceptable salt thereof.

7. The method of claim 4 wherein the compound is torasemide, or a pharmaceutically acceptable salt thereof.

8. The method of claim 4 wherein the composition is administered by microinjection.

9. The method of claim 4 wherein the composition further comprises a pharmaceutically acceptable carrier.

10. The method of claim 4 wherein the composition is administered topically.

11. The method of claim 10 wherein the composition further comprises a compound that enhances corneal penetration.

12. The method of claim 11 wherein the compound has an octanol:

water coefficient of at least 0.005.

13. The method of claim 12 wherein dosage of the compound is 50-100 microliters of a 5-10 mM solution of the compound per day.

14. The method of claim 10 wherein the composition further comprises 0.025% benzalkonium chloride.

15. The method of claim 10 wherein the compound is selected from the group of lipophilic derivatives of furosemide, piretanide, and torasemide.

16. The method of claim 15 wherein the compound has an octanol:

water coefficient of at least 0.01.

17. The method of claim 16 wherein the compound is a lipophilic derivative of torasemide.

18. The method of claim 16 wherein the compound is a lipophilic derivative of furosemide.

19. The method of claim 16 wherein the compound is a lipophilic derivative of piretanide.

20. The method of claim 4 wherein the patient is human and administration is in treatment of glaucoma.

21. The method of claim 20 wherein dosage of the compound is 50-100 microliters of a 5-10 mM solution of the compound per day.